Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 18, 2005 - Issue 1
Submit an article Journal homepage
113
Views
4
CrossRef citations to date
0
Altmetric
Articles

Diagnostic Molecular Pathology, Part 2: Proteomics and Clinical Applications of Molecular Diagnostics in Hematopathology

Georges J. NettoCorrespondence[email protected]
, MD &
Rana Saad
, PhD
Pages 7-12 | Published online: 11 Dec 2017

  • Liotta L, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286: 2211–2214.
  • Lau AT, He QY, Chiu JF. Proteomic technology and its biomedical applications. Acta Biochemica 2003;35: 965–975.
  • Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, Kuick R, Puravs E. Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2002;2: 69–75.
  • Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF III. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17: 301–307.
  • Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21: 1164–1177.
  • Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292: 587–592.
  • Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3: 267–275.
  • Fetsch PA, Simone NL, Bryant-Greenwood PK, Marincola FM, Filie AC, Petricoin EF, Liotta LA, Abati A. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 2002;118: 870–876.
  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359: 572–577.
  • Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76: 1560–1570.
  • Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 2002;95: 2276–2282.
  • de Mascarel A, Dubus P, Belleannee G, Megraud F, Merlio JP. Low prevalence of monoclonal B cells in Helicobacter pylori gastritis patients with duodenal ulcer. Hum Pathol 1998;29: 784–790.
  • Bagg A, Braziel RM, Arber DA, Bijwaard KE, Chu AY. Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J Mol Diagn 2002;4: 81–89.
  • Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004;37: 618–635.
  • Primo D, Tabernero MD, Rasillo A, Sayagues JM, Espinosa AB, Chillon MC, Garcia-Sanz R, Gutierrez N, Giralt M, Hagemeijer A, San Miguel JF, Orfao A. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003;17: 1124–1129.
  • Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, Bangerter M, Heimpel H. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol 1996;73: 225–230.
  • Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT. The emergence of Ph–, trisomy •8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31: 702–707.
  • Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001;128: 114–119.
  • Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102: 1160–1168.
  • Gozzetti A, Crupi R, Tozzuoli D. The use of fluorescence in situ hybridization (FISH) in chronic lymphocytic leukemia (CLL). Hematology 2004;9: 11–15.
  • Jamil A, Theil KS, Kahwash S, Ruymann FB, Klopfenstein KJ. TEL/AML-1 fusion gene: its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2000;122: 73–78.
  • Carroll WL, Bhojwani D, Min DJ, Raetz E, Relling M, Davies S, Downing JR, Willman CL, Reed JC. Pediatric acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2003;102–131.
  • Wassmann B, Gokbuget N, Scheuring UJ, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, Ottmann OG; GMALL Study Group. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol 2003;82: 716–720.
  • Merchant SH, Haines S, Hall B, Hozier J, Viswanatha DS. Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo. J Mol Diagn 2004;6: 271–274.
  • Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, Arias J, Deben G, Novo A, Bergua J, De La Serna J, Bueno J, Negri S, Beltran De Heredia JM, Martin G. All-trans retinoic acid and anthracycline monoche-motherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004 Aug 3 [Epub ahead of print].
  • Thiede C, Bornhauser M, Ehninger G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2004;112: 16–23.
  • Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am J Pharmacogenomics 2004;4: 177–187.
  • Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, Von Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004;22: 1696–1705.
  • Bader P, Kreyenberg H. Analysis of chimerism after stem cell transplantation. Methods Mol Med 2004;91: 247–264.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.